Aion Medicines
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Metabolic Diseases
Aion Medicines is developing ultra-long-acting therapeutics with convenient months-long dosing and improved efficacy and tolerability through pharmacokinetic enhancement. Our lead program, AM-710, is a "best-and-longest-in-class" incretin and GLP-1 receptor agonist, which has shown an in vivo half life of over 100 days, representing the longest-acting GLP-1 or weight loss agent of any class identified to date, and supporting the potential to be dosed monthly, quarterly, bi-annually and potentially longer. At ADA 2026, Aion is presenting data in obese monkeys demonstrating record setting weight loss with a single injection of AM-710. AM-710 is on track for IND submission at year end 2026 and clinical data generation in humans in 2027.
Company HQ City:
San Francisco
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2024
Lead Product in Development:
AM-710, best and longest in class GLP-1 with potential to be dosed monthly, quarterly, twice yearly, and even once yearly.
CEO
Alborz Yazdi, CEO
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
Mid-2027
What is your next catalyst (value inflection) update?
Phase 1 first in human data
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}